Chemokine Therapeutics has announced positive preclinical results for CTCE-9908 against a human prostate cancer cell line. CTCE-9908 prevented the spread of cancer in animals with established human prostate cancer to distant organs by 61 percent, following either daily subcutaneous or intraperitoneal administration of CTCE-9908.
The results are consistent with previously disclosed experimental animal models, where CTCE-9908 reduced bone cancer, skin cancer and lung cancer metastases by 50 percent to 70 percent. Further studies are planned to assess the cumulative benefits of CTCE-9908 in combination with the currently used anticancer chemotherapeutic agents.
CTCE-9908 is a small peptide analog of Chemokine SDF-1 produced through rational-based drug design to specifically block the function of CXCR4 receptors found on many common cancers. Leading cancer researchers have demonstrated that high CXCR4 expression in cancer cells is correlated to tumor progression, high metastasis rate and low survival rate. Blockage of CXCR4 reduces the growth of tumors by reducing blood vessel growth, which carries vital nutrients to a tumor.